<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VIIBRYD- vilazodone hydrochloride tablet </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VIIBRYD<span class="Sup">®</span> safely and effectively.  See full prescribing information for VIIBRYD.<br>VIIBRYD (vilazodone hydrochloride) tablets, for oral use<br>Initial U.S. Approval:  2011 </div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Antidepressants increase the risk of suicidal thoughts and behaviors in patients aged 24 years and younger (<a href="#s15">5.1</a>).</span></dd>
<dt>•</dt>
<dd><span class="Bold">Monitor for clinical worsening and emergence of suicidal thoughts and behaviors (<a href="#s15">5.1</a>).</span></dd>
<dt>•</dt>
<dd><span class="Bold">Safety and effectiveness of VIIBRYD have not been established in pediatric patients (<a href="#s48">8.4</a>).</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col width="79%">
<col width="21%">
<tbody class="Headless">
<tr>
<td class="Toprule" valign="top"><p class="Highlighta">Dosage and Administration (<a href="#s4">2</a>)  </p></td>
<td class="Toprule" valign="top"><p class="Highlighta">03/2015  </p></td>
</tr>
<tr>
<td valign="top"><p class="Highlighta">Warnings and Precautions (<a href="#s16">5.2</a>)  </p></td>
<td valign="top"><p class="Highlighta">04/2014  </p></td>
</tr>
<tr>
<td class="Botrule" valign="top"><p class="Highlighta">Warnings and Precautions (<a href="#s21">5.7</a>)  </p></td>
<td class="Botrule" valign="top"><p class="Highlighta">07/2014  </p></td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Antidepressants increase the risk of suicidal thoughts and behaviors in patients aged 24 years and younger (<a href="#s15">5.1</a>).</span></dd>
<dt>•</dt>
<dd><span class="Bold">Monitor for clinical worsening and emergence of suicidal thoughts and behaviors (<a href="#s15">5.1</a>).</span></dd>
<dt>•</dt>
<dd><span class="Bold">Safety and effectiveness of VIIBRYD have not been established in pediatric patients (<a href="#s48">8.4</a>).</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">VIIBRYD is indicated for the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) (<a href="#s3">1</a>).  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Recommended target dosage: 20 mg to 40 mg once daily with food (<a href="#s5">2.1</a>, <a href="#s60">12.3</a>) </dd>
<dt>•</dt>
<dd>To titrate: start with initial dosage of 10 mg once daily for 7 days, followed by 20 mg once daily. The dose may be increased up to 40 mg once daily after a minimum of 7 days between dosage increases (<a href="#s5">2.1</a>) </dd>
<dt>•</dt>
<dd>Prior to initiating VIIBRYD, screen for bipolar disorder (<a href="#s6">2.2</a>, <a href="#s18">5.4</a>) </dd>
<dt>•</dt>
<dd>When discontinuing VIIBRYD, reduce dosage gradually (<a href="#s8">2.4</a>, <a href="#s19">5.5</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets:  10 mg, 20 mg, and 40 mg (<a href="#s12">3</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs (<a href="#s13">4</a>) </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue VIIBRYD and initiate supportive treatment (<a href="#s16">5.2</a>) </dd>
<dt>•</dt>
<dd>Increased Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk (<a href="#s17">5.3</a>) </dd>
<dt>•</dt>
<dd>Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span>: Screen patients for bipolar disorder (<a href="#s18">5.4</a>). </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Can occur with treatment. Use with caution in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder (<a href="#s20">5.6</a>). </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle Closure Glaucoma</span>: Avoid use of antidepressants, including VIIBRYD, in patients with untreated anatomically narrow angles. (<a href="#s21">5.7</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥ 5% and at least twice the rate of placebo): <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (<a href="#s23">6</a>).  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Forest Laboratories, LLC. at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>CYP3A4 Inhibitors: The VIIBRYD dose should not exceed 20 mg once daily when co-administered with strong CYP3A4 inhibitors (<a href="#s8">2.4</a>, <a href="#s31">7</a>). </dd>
<dt>•</dt>
<dd>CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days (<a href="#s8">2.4</a>, <a href="#s31">7</a>). </dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: Third trimester use may increase risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> and withdrawal in the newborn (<a href="#s35">8.1</a>). </dd>
</dl></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
</div>
</div>
<div><div><div><div></div></div></div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS </a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage for Treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Screen for Bipolar Disorder Prior to Starting VIIBRYD </a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Switching to or from a Monoamine Oxidase Inhibitor Antidepressant </a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage Adjustments with CYP3A4 Inhibitors or Inducers </a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Discontinuing Treatment with VIIBRYD </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Suicidal Thoughts and Behavior in Children, Adolescents and Young Adults </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Increased Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Discontinuation Syndrome </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Drugs Having Clinically Important Interactions With VIIBRYD </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs Having No Clinically Important Interactions With VIIBRYD </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Lactation </a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use </a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Use in Other Patient Populations </a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance </a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> </a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE </a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION </a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of action </a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics </a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES </a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>WARNING: SUICIDAL THOUGHTS AND BEHAVIORS </h1>
<p class="First"><span class="Bold">Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger in short-term studies. Monitor closely for clinical worsening and for emergence of suicidal thoughts and behaviors. The safety and efficacy of VIIBRYD have not been established in pediatric patients <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>), and Use in Specific Populations (<a href="#s48">8.4</a>)]</span></span>. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE </h1>
<p class="First">VIIBRYD<span class="Sup">®</span> is indicated for the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) <span class="Italics">[see Clinical Studies (<a href="#s71">14</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage for Treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> </h2>
<p class="First">The recommended target dosage for VIIBRYD is 20 mg to 40 mg orally once daily with food <span class="Italics">[see Clinical Pharmacology (<a href="#s60">12.3</a>), Clinical Studies (<a href="#s71">14</a>)]</span>. To achieve the target dosage, titrate VIIBRYD as follows: </p>
<dl>
<dt>•</dt>
<dd>Start with an initial dosage of 10 mg once daily with food for 7 days, </dd>
<dt>•</dt>
<dd>Then increase to 20 mg once daily with food. </dd>
<dt>•</dt>
<dd>The dose may be increased up to 40 mg once daily with food after a minimum of 7 days between dosage increases. </dd>
</dl>
<p>If a dose is missed, it should be taken as soon as the patient remembers. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regular time. Two doses should not be taken at the same time. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Screen for Bipolar Disorder Prior to Starting VIIBRYD </h2>
<p class="First">Prior to initiating treatment with VIIBRYD or another antidepressant, screen patients for a personal or family history of bipolar disorder, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Switching to or from a Monoamine Oxidase Inhibitor Antidepressant </h2>
<p class="First">At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of VIIBRYD. In addition, at least 14 days must elapse after stopping VIIBRYD before starting an MAOI antidepressant <span class="Italics">[see Contraindications (<a href="#s13">4</a>), Warnings and Precautions (<a href="#s16">5.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosage Adjustments with CYP3A4 Inhibitors or Inducers </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.4.1"></a><p></p>
<p class="First"><span class="Underline">Patients receiving concomitant CYP3A4 inhibitors</span>: </p>
<p>During concomitant use of a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin, voriconazole), the VIIBRYD dose should not exceed 20 mg once daily. The original VIIBRYD dose level,  can be resumed when the CYP3A4 inhibitor is discontinued <span class="Italics">[see Drug Interactions (<a href="#s31">7</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.4.2"></a><p></p>
<p class="First"><span class="Underline">Patients receiving concomitant CYP3A4 inducers</span>: </p>
<p>Based on clinical response, consider increasing the dosage of VIIBRYD by 2-fold, up to a maximum 80 mg once daily, over 1 to 2 weeks in patients taking strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) for greater than 14 days. If CYP3A4 inducers are discontinued, gradually reduce the VIIBRYD dosage to its original level over 1 to 2 weeks <span class="Italics">[see Drug Interactions (<a href="#s31">7</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Discontinuing Treatment with VIIBRYD </h2>
<p class="First">Adverse reactions may occur upon discontinuation of VIIBRYD <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.5</a>)]</span>. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible. VIIBRYD should be down tapered from the 40 mg once daily dose to 20 mg once daily for 4 days, followed by 10 mg once daily for 3 days. Patients taking VIIBRYD 20 mg once daily should be tapered to 10 mg once daily for 7 days. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s12"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">VIIBRYD Tablets are available as 10 mg, 20 mg and 40 mg film-coated tablets. </p>
<dl>
<dt> </dt>
<dd>10 mg pink, oval tablet, debossed with 10 on one side </dd>
<dt> </dt>
<dd>20 mg orange, oval tablet, debossed with 20 on one side </dd>
<dt> </dt>
<dd>40 mg blue, oval tablet, debossed with 40 on one side </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s13"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS </h1>
<p class="First">VIIBRYD is contraindicated in: </p>
<dl>
<dt>•</dt>
<dd>Patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>), Drug Interactions (<a href="#s31">7</a>)]</span>. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s14"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Suicidal Thoughts and Behavior in Children, Adolescents and Young Adults </h2>
<p class="First">In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in patients age 24 years and younger was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in <a href="#_Reft1">Table 1</a>. </p>
<p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric studies. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. </p>
<a name="_Reft1"></a><table width="100%">
<caption><span>Table 1: Risk Differences of the Number of Patients with Suicidal Thoughts or Behaviors  in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients </span></caption>
<col width="19%">
<col width="81%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Age Range (years)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Drug-Placebo Difference in Number of Patients with Suicidal Thoughts or Behaviors per 1000 Patients Treated</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Increases Compared to Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">&lt;18 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 additional patients </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">18-24 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5 additional patients </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Decreases Compared to Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">25-64 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 fewer patient </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">≥65 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6 fewer patients </p></td>
</tr>
</tbody>
</table>
<p>It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. </p>
<p>Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing VIIBRYD, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </h2>
<p class="First">SNRIs and SSRIs, including VIIBRYD, can precipitate <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs <span class="Italics">[see Contraindications (<a href="#s13">4</a>) and Drug Interactions (<a href="#s31">7</a>)].</span> <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> can also occur when these drugs are used alone. Symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> were noted in 0.1% of MDD patients treated with VIIBRYD in premarketing clinical trials. </p>
<p><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> signs and symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). </p>
<p>The concomitant use of VIIBRYD with MAOIs is contraindicated. In addition, do not initiate VIIBRYD in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking VIIBRYD, discontinue VIIBRYD before initiating treatment with the MAOI <span class="Italics">[see Contraindications (<a href="#s13">4</a>), Drug Interactions (<a href="#s32">7.1</a>)].</span></p>
<p>Monitor all patients taking VIIBRYD for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. Discontinue treatment with VIIBRYD and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of VIIBRYD with other serotonergic drugs is clinically warranted, inform patients of the increased risk for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> and monitor for symptoms. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Increased Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </h2>
<p class="First">Drugs that interfere with serotonin reuptake inhibition, including VIIBRYD, increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>.  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events related to drugs that interfere with serotonin reuptake have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>. </p>
<p>Inform patients about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of VIIBRYD and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing VIIBRYD. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> </h2>
<p class="First">In patients with bipolar disorder, treating a <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> with VIIBRYD or another antidepressant may precipitate a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span>. In controlled clinical trials, patients with bipolar disorder were excluded; however, symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> were reported in 0.1% of undiagnosed patients treated with VIIBRYD. Prior to initiating treatment with VIIBRYD, screen patients for any personal or family history of bipolar disorder, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> <span class="Italics">[see Dosage and Administration (<a href="#s6">2.2</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Discontinuation Syndrome </h2>
<p class="First">Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, dysphoric mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">electric shock sensations</span>), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible <span class="Italics">[see Dosage and Administration (<a href="#s11">2.5</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </h2>
<p class="First">VIIBRYD has not been systematically evaluated in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder. Patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were excluded from clinical studies. VIIBRYD should be prescribed with caution in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> </h2>
<p class="First">The pupillary dilation that occurs following use of many antidepressant drugs including VIIBRYD may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including VIIBRYD, in patients with untreated anatomically narrow angles. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur as a result of treatment with SNRIs and SSRIs, including VIIBRYD.  Cases of serum sodium lower than 110 mmol/L have been reported.  Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>.  Signs and symptoms associated with more severe and/or acute cases have included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  In many cases, this <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). </p>
<p>In patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, discontinue VIIBRYD and institute appropriate medical intervention.  Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with SSRIs and SNRIs <span class="Italics">[see Use in Specific Populations (<a href="#s49">8.5</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s23"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS </h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling: </p>
<dl>
<dt>•</dt>
<dd>Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.1</a>)].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)].</span>
</dd>
<dt>•</dt>
<dd>Increased Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>)].</span>
</dd>
<dt>•</dt>
<dd>Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.4</a>)].</span>
</dd>
<dt>•</dt>
<dd>Discontinuation Syndrome <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.5</a>)].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see Warnings and Precautions (<a href="#s20">5.6</a>)]</span>
</dd>
<dt>•</dt>
<dd>Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> <span class="Italics">[see Warnings and Precautions (<a href="#s21">5.7</a>)].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> <span class="Italics">[see Warnings and Precautions (<a href="#s22">5.8</a>)].</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions and varying lengths of time, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice. </p>
<p>The most commonly observed adverse reactions in VIIBRYD-treated patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) in placebo-controlled studies (incidence ≥ 5% and at least twice the rate of placebo) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Patient Exposure</span></p>
<p>The safety of VIIBRYD was evaluated in 3,007 patients (18-70 years of age) diagnosed with MDD who participated in clinical studies, representing 676 patient-years of exposure. In an open-label 52 week study at 40 mg daily, 599 patients were exposed to VIIBRYD for a total of 348 patient-years. </p>
<p>The adverse reaction information presented below was derived from studies of VIIBRYD 20 mg and 40 mg daily in patients with MDD including: </p>
<dl>
<dt>•</dt>
<dd>Four placebo-controlled 8 to 10-week studies in 2,233 patients, including 1,266 VIIBRYD-treated patients; and </dd>
<dt>•</dt>
<dd>An open-label 52-week study of 599 VIIBRYD-treated patients. </dd>
</dl>
<p>These studies included a titration period of 10 mg daily for 7 days, followed by 20 mg daily for 7 days or to 40 mg daily over 2 weeks. In these clinical trials, VIIBRYD was administered with food. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Adverse reactions reported as reasons for discontinuation of treatment</span></p>
<p>In these studies, 7.3% of the VIIBRYD-treated patients discontinued treatment due to an adverse reaction, compared with 3.5% of placebo-treated patients. The most common adverse reaction leading to discontinuation in at least 1% of the VIIBRYD-treated patients in the placebo-controlled studies was <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.4%). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Common adverse reactions in placebo-controlled MDD studies</span></p>
<p><a href="#_Reft2">Table 2</a> shows the incidence of common adverse reactions occuring in ≥ 2% of VIIBRYD-treated patients and greater than the rate of placebo-treated patients in MDD Studies.  There were no dose-related adverse reactions between 20 mg and 40 mg reported. </p>
<a name="_Reft2"></a><table width="100%">
<caption><span>Table 2:  Common Adverse Reactions Occurring in ≥ 2% of VIIBRYD-treated Patients and Greater than the Rate of Placebo-Treated Patients </span></caption>
<col width="52%">
<col width="16%">
<col width="17%">
<col width="16%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">System Organ Class</span><br><span class="Bold">Preferred Term</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<br><span class="Bold">Placebo</span><br><span class="Bold">N=967</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">VIIBRYD</span><br><span class="Bold">20 mg/day</span><br><span class="Bold">N=288</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">VIIBRYD</span><br><span class="Bold">40 mg/day</span><br><span class="Bold">N=978</span>
</th>
</tr></thead>
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="4" valign="top">
<span class="Sup">1</span> Includes <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. </td></tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">
<span class="Sup">2</span> Includes <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span> </td></tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">
<span class="Sup">3</span> Includes <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, and <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless legs syndrome</span> </td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="4" valign="top">Sexual adverse reactions are presented in <a href="#_Reft3">Table 3</a>
</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">26% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">29% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">22% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">24% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><span class="Sup">1</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><span class="Sup">2</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">14% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">14% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Psychiatric disorders</span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span><span class="Sup">3</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">General disorders</span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">&lt;1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Metabolism and nutrition disorders</span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Investigations</span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">      Increased weight </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2% </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Underline">Sexual adverse reactions</span></p>
<p><a href="#_Reft3">Table 3</a> displays the most common sexual adverse reactions in the placebo-controlled MDD studies. </p>
<a name="_Reft3"></a><table width="100%">
<caption><span>Table 3:  Common Sexual Adverse Reactions Occurring in ≥ 2% of VIIBRYD-treated Patients and Greater than the Rate of Placebo-Treated Patients </span></caption>
<col width="23%">
<col width="22%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">− Not applicable*Includes abnormal orgasm and <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span> </td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">Preferred Term</span><br></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Males</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Females</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><br><span class="Bold">Placebo</span><br><span class="Bold">N=416</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">VIIBRYD 20 mg/day</span><br><span class="Bold">N=122</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">VIIBRYD</span><br><span class="Bold">40 mg/day</span><br><span class="Bold">N=417</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><br><span class="Bold">Placebo</span><br><span class="Bold">N=551</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">VIIBRYD 20 mg/day</span><br><span class="Bold">N=166</span></p></td>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">VIIBRYD</span><br><span class="Bold">40 mg/day</span><br><span class="Bold">N=561</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Abnormal Orgasm* </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">&lt;1% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span> </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">- </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">- </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">- </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span> </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">&lt;1% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">&lt;1% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2% </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation disorder</span> </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2% </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">- </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">- </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">- </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Underline">Other adverse reactions observed in clinical studies</span></p>
<p>The following list does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo. </p>
<p>Reactions are categorized by body system according to the following definitions:  <span class="Italics">frequent</span> adverse reactions are those occurring in at least 1/100 patients; <span class="Italics">infrequent</span> adverse reactions are those occurring in 1/100 to 1/1000 patients; <span class="Italics">rare</span> reactions are those occurring in fewer than 1/1000 patients: </p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: <span class="Italics">infrequent</span>: <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span> </dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>: <span class="Italics">infrequent:</span> <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="Italics">rare:</span> <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> </dd>
<dt> </dt>
<dd>Nervous System: <span class="Italics">frequent</span>: sedation, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>; <span class="Italics">infrequent</span>: <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> </dd>
<dt> </dt>
<dd>Psychiatric disorders: <span class="Italics">infrequent</span>: <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span> </dd>
<dt> </dt>
<dd>Skin and subcutaneous tissue disorders: <span class="Italics">infrequent</span>: <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span> </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience </h2>
<p class="First">The following adverse reactions have been identified during post-approval use of VIIBRYD. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure. Reports of adverse reactions temporally associated with VIIBRYD that have been received since market introduction and that are not listed above include the following: </p>
<p>General Disorders and Administration Site Conditions:  <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> </p>
<p>Psychiatric Disorders: <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> </p>
<p>Skin and subcutaneous tissue disorders: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span> </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s31"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Drugs Having Clinically Important Interactions With VIIBRYD </h2>
<table width="100%">
<caption><span>Table 4:  Clinically Important Drug Interactions with VIIBRYD </span></caption>
<col width="18%">
<col width="36%">
<col width="46%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Concomitant Drug Name or Drug Class</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Clinical Rationale</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Clinical Recommendation</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Monoamine Oxidase Inhibitors (MAOIs) </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">The concomitant use of MAOIs and serotonergic drugs including VIIBRYD increases the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">VIIBRYD is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue <span class="Italics">[see Contraindications (<a href="#s13">4</a>), Dosage and Administration (<a href="#s7">2.3</a>), and Warnings and Precautions (<a href="#s16">5.2</a>)].</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Other Serotonergic Drugs </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">The concomitant use of serotonergic drugs including VIIBRYD and other serotonergic drugs increases the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly during VIIBRYD initiation.  If <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> occurs, consider discontinuation of VIIBRYD and/or concomitant serotonergic drugs <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>)].</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Antiplatelet Agents and Anticoagulants </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">Serotonin release by platelets plays an important role in hemostasis.  The concurrent use of an antiplatelet agent or anticoagulant with VIIBRYD may potentiate the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">Inform patients of the increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with the concomitant use of VIIBRYD and antiplatelet agents and anticoagulants.  For patients taking warfarin, carefully monitor the international normalized ratio (INR) when initiating or discontinuing VIIBRYD <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>)].</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin, voriconazole) </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">The concomitant use of VIIBRYD and strong CYP3A4 inhibitors increased the exposure of vilazodone compared to the use of VIIBRYD alone <span class="Italics">[see Clinical Pharmacology (<a href="#s60">12.3</a>)].</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">The VIIBRYD dose should not exceed 20 mg once daily with the concomitant use of a strong CYP3A4 inhibitor <span class="Italics">[see Dosage and Administration (<a href="#s8">2.4</a>), Clinical Pharmacology (<a href="#s60">12.3</a>)].</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Strong CYP3A4 Inducers (e.g.,<br>carbamazepine, phenytoin, rifampin) </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">The concomitant use of VIIBRYD and strong CYP3A4 inducers decreased the exposure of vilazodone compared to the use of VIIBRYD alone <span class="Italics">[see Clinical Pharmacology (<a href="#s60">12.3</a>)].</span></p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">Based on clinical response, consider increasing the dosage of VIIBRYD, over 1 to 2 weeks in patients taking strong CYP3A4 inducers for greater than 14 days <span class="Italics">[see Dosage and Administration (<a href="#s8">2.4</a>), Clinical Pharmacology (<a href="#s60">12.3</a>)].</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Digoxin </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">Digoxin is a narrow therapeutic index drug. Concomitant use of VIIBRYD increased digoxin concentrations <span class="Italics">[see Clinical Pharmacology (<a href="#s60">12.3</a>)]</span>. </p></td>
<td class="Botrule Rrule" valign="middle"><p class="First">Measure serum digoxin concentrations before initiating concomitant use of VIIBRYD. Continue monitoring and reduce digoxin dose as necessary.<br></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs Having No Clinically Important Interactions With VIIBRYD </h2>
<p class="First">Based on pharmacokinetic studies, no dosage adjustment is required for drugs that are substrates of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and/or P-glycoprotein (except narrow therapeutic index drugs, e.g., digoxin), when VIIBRYD is administered concomitantly <span class="Italics">[see Drug Interactions (<a href="#s32">7.1</a>), Clinical Pharmacology (<a href="#s60">12.3</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s34"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s35"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies of VIIBRYD in pregnant women. The background risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> for the indicated population is unknown.  However, the background risk in the U.S. general population of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> is 2-4% and of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> is 15-20% of clinically recognized pregnancies.   In animal reproduction studies, oral administration of vilazodone during the period of organogenesis at doses up to 48 and 17 times the maximum recommended human dose (MRHD) in rats and rabbits, respectively, resulted in decreased fetal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and delayed skeletal ossification but no teratogenic effects were observed.  Decreased fetal body weight and delayed skeletal ossification were not observed at doses up to 10 and 4 times the MRHD in rats and rabbits, respectively <span class="Italics">[see Data]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Italics">Clinical Considerations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-8.1.2.1"></a><p></p>
<p class="First"><span class="Underline">Disease-associated maternal and/or embryo/fetal risk</span></p>
<p>A prospective, longitudinal study followed 201 pregnant women with a history of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> who were euthymic and taking antidepressants at the beginning of pregnancy.  The women who discontinued antidepressants during pregnancy were more likely to experience a relapse of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> than women who continued antidepressants.  Consider the risks of untreated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-8.1.2.2"></a><p></p>
<p class="First"><span class="Underline">Fetal/Neonatal adverse reactions</span></p>
<p>Exposure to SSRIs and SNRIs, including VIIBRYD, in late pregnancy may lead to an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN).  Monitor neonates who were exposed to VIIBRYD in the third trimester of pregnancy for PPHN and drug discontinuation syndrome <span class="Italics">[</span>see <span class="Italics"><a href="#_Refs40">Data</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Italics">Data</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-8.1.3.1"></a><p></p>
<p class="First"><span class="Underline">Human Data</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-8.1.3.1.1"></a><p></p>
<p class="First"><span class="Italics">Third Trimester Exposure</span></p>
<p>Neonates exposed to SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs) late in the third trimester, have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. These findings are based on post-marketing reports. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. In some cases, the clinical picture was consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[</span>see <span class="Italics">Warnings and Precautions (<a href="#s16">5.2</a>)].</span></p>
<p>Exposure during late pregnancy to SSRIs may have an increased risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). PPHN occurs in 1-2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy. A study of 831,324 infants born in Sweden in 1997-2005 found a PPHN risk ratio of 2.4 (95% CI 1.2-4.3) associated with patient-reported maternal use of SSRIs "in early pregnancy" and a PPHN risk ratio of 3.6 (95% CI 1.2-8.3) associated with a combination of patient-reported maternal use of SSRIs "in early pregnancy" and an antenatal SSRI prescription "in later pregnancy." </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-8.1.3.2"></a><p></p>
<p class="First"><span class="Underline">Animal Data</span></p>
<p>No teratogenic effects were observed when vilazodone was given to pregnant rats or rabbits during the period of organogenesis at oral doses up to 200 and 36 mg/kg/day, respectively. These doses are 48 and 17 times, in rats and rabbits, respectively, the maximum recommended human dose (MRHD) of 40 mg on a mg/m<span class="Sup">2</span> basis. Fetal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was reduced, and skeletal ossification was delayed in both rats and rabbits at these doses; these effects were not observed at doses up to 10 times the MRHD in rats or 4 times the MRHD in rabbits. </p>
<p>When vilazodone was administered to pregnant rats at an oral dose of 30 times the MRHD during the period of organogenesis and throughout pregnancy and lactation, the number of live born pups was decreased. There was an increase in early postnatal pup mortality, and among surviving pups there was decreased body weight, delayed maturation, and decreased fertility in adulthood. There was some maternal toxicity at this dose.  These effects were not seen at 6 times the MRHD. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Lactation </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-8.2.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>There are no data on the presence of  vilazodone in human milk, the effects of vilazodone on the breastfed infant, or the effects of the drug on milk production. However, vilazodone is excreted in rat milk <span class="Italics">[see <a href="#_Refs46">Data</a>]</span>. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VIIBRYD and any potential adverse effects on the breastfed child from VIIBRYD or from the underlying maternal condition. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-8.2.1.1"></a><p></p>
<p class="First"><span class="Italics">Data</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-8.2.1.1.1"></a><p></p>
<p class="First"><span class="Underline">Animal Data</span></p>
<p>Administration of vilazodone to lactating rats at an oral dose of 30 times the maximum recommended human dose (MRHD), resulted in early postnatal pup mortality, and among surviving pups there was decreased body weight and delayed maturation. </p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s48"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First">Clinical studies on the use of VIIBRYD in pediatric patients have not been conducted; therefore, the safety and effectiveness of VIIBRYD in pediatric patients have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients <span class="Italics">[see <a href="#s2">Boxed Warning</a> and Warnings and Precautions (<a href="#s15">5.1</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s49"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use </h2>
<p class="First">Based on a pharmacokinetic study, no dosage adjustment of VIIBRYD is recommended on the basis of age (see <a href="#_Reffig2">Figure 2</a>). Results from pharmacokinetic study of a single 20 mg VIIBRYD dose in geriatric subjects (&gt; 65 years-old) vs. younger subjects (24-55 years-old) demonstrated that the pharmacokinetics were generally similar between the two age groups <span class="Italics">[see Clinical Pharmacology (<a href="#s60">12.3</a>)].</span></p>
<p>Clinical studies of VIIBRYD did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Of the 3,077 patients in clinical studies with VIIBRYD, 65 (2.2%) were 65 years of age or older, and 378 (12.6%) were 55 to 64 years of age. In general, dose selection for an elderly patient should be conservative, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
<p>Serotonergic antidepressants have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse reaction <span class="Italics">[see Warnings and Precautions (<a href="#s22">5.8</a>)]</span>. No other differences in adverse reactions were observed between geriatric and younger patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Use in Other Patient Populations </h2>
<p class="First">No dosage adjustment of VIIBRYD is necessary on the basis of gender, renal function (mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, glomerular filtration rate: 15-90 mL/minute), or hepatic function (mild to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, Child-Pugh score: 5-15 <span class="Italics">[see Clinical Pharmacology (<a href="#s60">12.3</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s51"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </h1>
<div class="Section" data-sectionCode="34085-1">
<a name="s52"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance </h2>
<p class="First">VIIBRYD is not a controlled substance. </p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="s53"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> </h2>
<p class="First">VIIBRYD has been systematically studied in animals and did not demonstrate abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> potential. While VIIBRYD has not been systematically studied in humans for its potential for abuse, there was no suggested evidence of drug-seeking behavior in the clinical studies. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s54"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE </h1>
<p class="First">There is limited clinical trial experience regarding human <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with VIIBRYD. The adverse reactions associated with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of VIIBRYD at doses of 200-280 mg (5 to 7 times the recommended dosage) as observed in clinical trials included <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>. </p>
<p>For current information on the management of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, contact a poison control center at 1-800-222-1222. </p>
<p>No specific antidotes for vilazodone are known. Removal of vilazodone by dialysis has not been studied; however, the high volume of distribution of vilazodone suggests that dialysis will not be effective in reducing vilazodone plasma concentrations. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s55"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION </h1>
<p class="First">VIIBRYD tablets for oral administration contain polymorph Form IV vilazodone hydrochloride (HCl), a selective serotonin reuptake inhibitor and a 5HT<span class="Sub">1A</span> receptor partial agonist. </p>
<p>Vilazodone HCl is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1<span class="Italics">H</span>-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1). Its molecular weight is 477.99.  The structural formula is: </p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242&amp;name=vii00-0013-01.jpg">
</div>
<p>In addition to the active ingredient, VIIBRYD tablets contain the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, FD&amp;C Blue #1 (40 mg only), FD&amp;C Yellow #6 (20 mg only) and FD&amp;C Red #40 (10 mg only). </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s56"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s57"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of action </h2>
<p class="First">The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT<span class="Sub">1A</span> receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone's antidepressant effect are unknown. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s58"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics </h2>
<p class="First">Vilazodone binds with high affinity to the serotonin reuptake site (Ki= 0.1 nM), but not to the norepinephrine (Ki=56 nM) or dopamine (Ki=37 nM) reuptake sites. Vilazodone potently and selectively inhibits reuptake of serotonin (IC<span class="Sub">50</span>= 1.6 nM).  Vilazodone also binds selectively with high affinity to 5-HT<span class="Sub">1A</span> receptors (IC<span class="Sub">50</span>=2.1 nM) and is a 5-HT<span class="Sub">1A</span> receptor partial agonist. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Underline">Cardiac Electrophysiology</span></p>
<p>Treatment with VIIBRYD did not prolong the QTc interval. The effect of VIIBRYD [20, 40, 60, and 80 mg (2 times the recommended dosage)] on the QTc interval was evaluated in a randomized, placebo-, and active-controlled (moxifloxacin 400 mg), parallel-group, thorough QTc study in 157 healthy subjects. The study demonstrated an ability to detect small effects. The upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc interval was below 10 msec, based on the individual correction method (QTcI). Thus, at doses of 2 times the recommended dosage, VIIBRYD did not prolong the QTc interval to a clinically relevant extent. </p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s60"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<p class="First">Vilazodone activity is due primarily to the parent drug.  The pharmacokinetics of vilazodone (5 mg – 80 mg) are dose-proportional. Accumulation of vilazodone after administration of single VIIBRYD doses did not vary with dose, and steady-state was achieved in about 3 days. Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours. At steady-state, after daily dosing of VIIBRYD 40 mg under fed conditions, the mean C<span class="Sub">max</span> value was 156 ng/mL, and the mean AUC (<span class="Sub">0-24 hours</span>) value was 1645 ng·h/mL. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Vilazodone concentrations peaked at a median of 4-5 hours (T<span class="Sub">max</span>) after VIIBRYD administration and declined with a terminal half-life of approximately 25 hours.  The absolute bioavailability of vilazodone was 72% with food.Vilazodone AUC and C<span class="Sub">max</span>  in the fasted state can be decreased by approximately 50% and 60%, respectively, compared to the fed state.  Administration without food can result in inadequate drug concentrations and may reduce effectiveness. </p>
<p>Coadministration of VIIBRYD with ethanol or with a proton pump inhibitor (pantoprazole) did not affect the rate or extent of vilazodone absorption. In addition, neither the T<span class="Sub">max</span> nor terminal elimination rate of vilazodone was altered by coadministration with either pantoprazole or ethanol. </p>
<p>Absorption is decreased by approximately 25% if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurs within 7 hours of ingestion; no replacement dose is needed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Vilazodone is widely distributed and approximately 96-99% protein-bound. Administration of VIIBRYD to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, because vilazodone is highly bound to plasma protein.  The interaction between vilazodone and other highly protein-bound drugs has not been evaluated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-12.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination</span></p>
<p>VIIBRYD is extensively metabolized through CYP and non-CYP pathways (possibly by carboxylesterase), with only 1% of the dose recovered in the urine and 2% of the dose recovered in the feces as unchanged vilazodone. CYP3A4 is primarily responsible for its metabolism among CYP pathways, with minor contributions from CYP2C19 and CYP2D6. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-12.3.4"></a><p></p>
<p class="First"><span class="Underline">Drug Interaction Studies</span></p>
<p><a href="#_Reffig1">Figure 1</a> below includes the impact of other drugs on the pharmacokinetics of vilazodone <span class="Italics">[see Drug Interactions (<a href="#s31">7</a>)].</span></p>
<p><span class="Bold">Figure 1. Effect of Other Drugs on Vilazodone Pharmacokinetics</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242&amp;name=vii00-0013-02.jpg">
</div>
<p><span class="Italics">In vitro</span> studies indicate that vilazodone is unlikely to inhibit or induce the metabolism of substrates for CYP1A1, 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4 or 3A5, except for CYP2C8. The effect of vilazodone on CYP2C8 activity has not been tested <span class="Italics">in vivo</span>.   <a href="#_Reffig2">Figure 2</a> below includes the impact of vilazadone on the pharmacokinetics of other drugs <span class="Italics">in vivo</span>. </p>
<p><span class="Bold">Figure  2. Impact of Vilazodone on Other Drug Pharmacokinetics</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242&amp;name=vii00-0013-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-12.3.5"></a><p></p>
<p class="First"><span class="Underline">Studies in Specific Populations:</span></p>
<p>The presence of mild to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or mild to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> did not affect the apparent clearance of vilazodone (see <a href="#_Reffig3">Figure 3</a>).  There were no pharmacokinetic differences of vilazodone in geriatric patients compared to younger patients, or between males and females (see <a href="#_Reffig3">Figure 3</a>). </p>
<p><span class="Bold">Figure 3: Impact of Intrinsic Factors on Vilazodone Pharmacokinetics</span></p>
<div class="Figure">
<a name="f04"></a><img alt="Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242&amp;name=vii00-0013-04.jpg">
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s66"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s67"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Carcinogenicity studies were conducted in which B6C3F1mice and Wistar rats were given oral doses of vilazodone up to 135 and 150 mg/kg/day, respectively, for 2 years. These doses are approximately 16.5 and 36 times the maximum recommended human dose (MRHD) of 40 mg, respectively, on a mg/m<span class="Sup">2</span> basis. </p>
<p>In mice, the incidence of hepatocellular carcinomas was increased in males at 16.5 times the MRHD; this finding was not observed at 5.5 times the MRHD. The incidence of malignant mammary gland tumors was numerically increased in females at 5.5 and 16.5 times the MRHD, with statistical significance at 16.5 the MRHD; this finding was not observed at 1.8 times the MRHD. Elevated prolactin levels were observed in a 2-week study of vilazodone administered at 5.5 and 33 times the MRHD. Increases in prolactin levels are known to cause mammary tumors in rodents. </p>
<p>In the rat study, vilazodone was not carcinogenic in either sex at doses up to 36 times the MRHD. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span></p>
<p>Vilazodone was not mutagenic in the <span class="Italics">in vitro</span> bacterial reverse mutation assay (Ames test). Vilazodone was negative in the <span class="Italics">in vitro</span> V79/HGRPT mammalian cell forward mutation assay. Vilazodone was clastogenic in two <span class="Italics">in vitro</span> mammalian cell chromosome aberration assays. However, vilazodone was negative for clastogenic activity in both an <span class="Italics">in vivo</span> rat bone marrow chromosome aberration assay and a micronucleus test. Vilazodone was also negative in an <span class="Italics">in vivo/in vitro</span> unscheduled DNA synthesis assay in rats. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span></p>
<p>Treatment of rats with vilazodone at a dose of 125 mg/kg, which is 30 times the MRHD of 40 mg on a mg/m<span class="Sup">2</span> basis, caused impairment of male fertility with no effect on female fertility. Impaired male fertility was not observed at 6 times the MRHD. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s71"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES </h1>
<p class="First">The efficacy of VIIBRYD as a treatment for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> was demonstrated in four multicenter, randomized, double-blind, placebo-controlled studies in adult (18-70 years of age) outpatients who met the Diagnostic and Statistical Manual of <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Mental Disorders</span> (DSM-IV-TR) criteria for MDD. Three 8-week studies evaluated the efficacy of VIIBRYD 40 mg (Studies 1-3) and one 10-week study (Study 4) evaluated the efficacy of VIIBRYD 20 mg and 40 mg (see <a href="#_Reft5">Table 5</a>). In these studies, patients were randomized to either 20 mg or 40 mg, or placebo once daily with food. Patients were either titrated over 1week to a dose of 20 mg daily or over 2 weeks to a dose of 40 mg once daily of VIIBRYD with food. VIIBRYD was superior to placebo in the improvement of <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> as measured by the change from baseline to endpoint visit in the Montgomery-Asberg <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale (MADRS) total score for both doses. The MADRS is a ten-item, clinician-rated scale used to assess severity of <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>. Scores on the MADRS range from 0 to 60, with higher scores indicating more severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Clinical Global Improvement - Severity (CGI-S) was evaluated in Studies 3 and 4. VIIBRYD 20 mg and 40 mg demonstrated superiority over placebo as measured by improvement in CGI-S score. </p>
<a name="_Reft5"></a><table width="100%">
<caption><span>Table 5:  Summary of Results for the Primary Efficacy Endpoint - MADRS Total Score </span></caption>
<col width="10%">
<col width="21%">
<col width="21%">
<col width="14%">
<col width="16%">
<col width="18%">
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="6" valign="top">SD = standard deviation; SE = standard error; LS Mean = least-square mean; CI = confidence interval </td></tr>
<tr><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Sup">a</span> based on patients who took study medication and had baseline and postbaseline MADRS assessments <br><span class="Sup">b</span> difference (drug minus placebo) in least-square mean change from baseline to endpoint </td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="6" valign="top">* All VIIBRYD treatment dose groups remained statistically significant compared with placebo after adjusting for multiplicity </td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Study</span><br><span class="Bold">Number</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Treatment Group</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Number of Patients <span class="Sup">a</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Mean Baseline Score (SD)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">LS Mean Change from Baseline (SE)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo-subtracted Difference <span class="Sup">b </span></span><br><span class="Bold">(95% CI)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">Study 1<br></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">VIIBRYD 40mg/day </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">198 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">30.8 (3.90) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-12.9 (0.77) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-3.2 (-5.2, -1.3) </p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Placebo </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">199 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">30.7 (3.93) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-9.6 (0.76) </p></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">Study 2<br></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">VIIBRYD 40 mg/day </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">231 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">31.9 (3.50) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-13.3 (0.90) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-2.5 (-4.4, -0.6) </p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Placebo </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">232 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">32.0 (3.63) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-10.8 (0.90) </p></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First">Study 3<br></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">VIIBRYD 40 mg/day </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">253 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">30.7 (3.3) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-16.1 (0.64) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-5.1 (-6.9, -3.3) </p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Placebo </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">252 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">30.9 (3.3) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-11.0 (0.65) </p></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">VIIBRYD 20 mg/day* </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">288 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">31.3 (3.5) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-17.3 (0.63) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-2.6 (-4.3, -0.8) </p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">Study 4 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">VIIBRYD 40 mg/day* </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">284 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">31.2 (3.8) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-17.6 (0.65) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-2.8 (-4.6, -1.1) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Placebo </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">281 </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">31.4 (3.8) </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-14.8 (0.62) </p></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
</tbody>
</table>
<p>Baseline demographics information were generally similar across all treatment groups. Examination of population subgroups based on age (there were few patients over 65), gender and race did not reveal any clear evidence of differential responsiveness. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s72"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING </h1>
<p class="First">VIIBRYD (vilazodone HCl) tablets are supplied in the following configurations: </p>
<table width="58.52%">
<col width="16%">
<col width="28%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Tablet</span><br><span class="Bold">Strength</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Tablet</span><br><span class="Bold">Color/Shape</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Tablet</span><br><span class="Bold">Markings</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">40 mg </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">blue, oval tablet </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">debossed with<br>40 on one side </p></td>
</tr>
</tbody>
</table>
<p>Viibryd (vilazodone HCl) 40 mg are available in bottles of 960 tablets, NDC 55154-4624-2.</p>
<p>Viibryd (vilazodone HCl) 40 mg are available in bottles of 1920 tablets, NDC 55154-4624-8.</p>
<p>Store tablets at 25°C (77°F).  Excursions permitted to 15°C - 30°C (59°F - 86°F) [<span class="Italics">see USP Controlled Room Temperature</span>]. </p>
<p>Repackaged By:</p>
<p>Cardinal Health</p>
<p>Zanesville, OH 43701</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s73"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-16.1"></a><p></p>
<p class="First"><span class="Underline">Suicidal Thoughts and Behaviors</span></p>
<p>Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider [<span class="Italics">see Box Warning and Warnings and Precautions (<a href="#s15">5.1</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-16.2"></a><p></p>
<p class="First"><span class="Underline">Dosage and Administration</span></p>
<p>Instruct patients to take VIIBRYD with food and to follow prescribed dosage instructions <span class="Italics">[see Dosage and Administration (<a href="#s5">2.1</a>, <a href="#s7">2.3</a>, <a href="#s8">2.4</a>, <a href="#s11">2.5</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-16.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span></p>
<p>Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly with the concomitant use of VIIBRYD with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Patients should contact their health care provider or report to the emergency room if they experience signs or symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.2</a>) and Drug Interactions (<a href="#s31">7</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-16.4"></a><p></p>
<p class="First"><span class="Underline">Increased Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
<p>Inform patients about the concomitant use of VIIBRYD with aspirin, NSAIDs, other antiplatelet drugs, warfarin, or other anticoagulants because the combined use of drugs that interfere with serotonin reuptake (e.g., VIIBRYD) and these medications has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Advise them to inform their health care providers if they are taking or planning to take any prescription or over-the-counter medications that increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-16.5"></a><p></p>
<p class="First"><span class="Underline">Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></span></p>
<p>Advise patients and their caregivers to observe for signs of activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> and instruct them to report such symptoms to the healthcare provider <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.4</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s79"></a><a name="section-16.6"></a><p></p>
<p class="First"><span class="Underline">Discontinuation Syndrome</span></p>
<p>Advise patients not to abruptly discontinue VIIBRYD and to discuss any tapering regimen with their healthcare provider. Adverse reactions can occur when VIIBRYD is discontinued <span class="Italics">[see Warnings and Precautions (<a href="#s19">5.5</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-16.7"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>Caution patients about using VIIBRYD if they have a history of a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder <span class="Italics">[see Warnings and Precautions (<a href="#s20">5.6</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-16.8"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Advise patients to notify their healthcare provider if they develop an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> <span class="Italics">[see Adverse Reactions (<a href="#s30">6.2</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-16.9"></a><p></p>
<p class="First"><span class="Underline">Concomitant Medications</span></p>
<p>Advise patients to inform their health care providers if they are taking, or plan to take any prescription or over-the-counter medications since there is a potential for interactions <span class="Italics">[see Drug Interactions (<a href="#s32">7.1</a>)].</span></p>
<p>Repackaged by:</p>
<p>Cardinal Health</p>
<p>Zanesville, OH 43701 </p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="e82"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">VIIBRYD® <span class="Italics"><span class="Underline">[vī-brid]</span></span></span><br>(vilazodone hydrochloride)<br><span class="Bold">Tablets</span></p>
<p>Read this Medication Guide carefully before you start taking VIIBRYD and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. </p>
<p><span class="Bold">What is the most important information I should know about VIIBRYD?</span></p>
<p><span class="Bold">VIIBRYD and other antidepressant medicines may cause serious side effects.</span></p>
<p><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if there is an emergency:</span></p>
<p><span class="Bold">1. Suicidal thoughts or actions:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">VIIBRYD and other antidepressant medicines may increase suicidal thoughts or actions</span> in some people 24 years of age and younger, especially within the <span class="Bold">first few months of treatment or when the dose is changed.</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> or other serious mental illnesses are the most important causes of suicidal thoughts or actions. </dd>
<dt>•</dt>
<dd>Watch for these changes and call your healthcare provider right away if you notice: </dd>
<dt>•</dt>
<dd>New or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe. </dd>
<dt>•</dt>
<dd>Pay particular attention to such changes when VIIBRYD is started or when the dose is changed. </dd>
<dt>•</dt>
<dd>Keep all follow-up visits with your healthcare provider and call between visits if you are worried about symptoms.  <br><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span><dl>
<dt>•</dt>
<dd>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> </dd>
<dt>•</dt>
<dd>acting on dangerous impulses </dd>
<dt>•</dt>
<dd>acting aggressive or violent </dd>
<dt>•</dt>
<dd>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying </dd>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </dd>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> </dd>
<dt>•</dt>
<dd>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>, angry or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span> </dd>
<dt>•</dt>
<dd>trouble sleeping </dd>
<dt>•</dt>
<dd>an increase in activity or talking more than what is normal for you (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>) </dd>
<dt>•</dt>
<dd>other unusual changes in behavior or mood </dd>
</dl>
</dd>
</dl>
<p><span class="Bold">2.  <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span>: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or other changes in mental status </dd>
<dt>•</dt>
<dd>coordination problems or <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span> (overactive reflexes) </dd>
<dt>•</dt>
<dd>fast heartbeat, high or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle stiffness</span> or tightness </dd>
</dl>
<p><span class="Bold">3.  Increased chance of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span>: VIIBRYD and other antidepressant medicines may increase your chance of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, especially if you take the blood thinner warfarin (Coumadin<span class="Sup">®</span>, Jantoven<span class="Sup">®</span>), a non-steroidal anti-inflammatory drug (NSAID), or aspirin. </p>
<p><span class="Bold">4.  <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic episodes</span>:</span></p>
<dl>
<dt>•</dt>
<dd>greatly increased energy </dd>
<dt>•</dt>
<dd>severe trouble sleeping </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4115026" conceptname="Racing thoughts">racing thoughts</span> </dd>
<dt>•</dt>
<dd>reckless behavior </dd>
<dt>•</dt>
<dd>unusually grand ideas </dd>
<dt>•</dt>
<dd>excessive happiness or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> </dd>
<dt>•</dt>
<dd>talking more or faster than usual </dd>
</dl>
<p><span class="Bold">5. Discontinuation symptoms. Do not suddenly stop VIIBRYD without first talking to your healthcare provider</span>. Stopping VIIBRYD suddenly may cause serious symptoms including: </p>
<dl>
<dt>•</dt>
<dd>flu-like symptoms such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, high or low mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, feeling <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439396" conceptname="Injury due to electrical exposure">electric shock</span>-like sensations, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> </dd>
</dl>
<p>If your healthcare provider decides that you should stop taking VIIBRYD, your healthcare provider should slowly decrease (taper) your dose. </p>
<p><span class="Bold">6.  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</span></p>
<p><span class="Bold">7. <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> (angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>):</span> Many antidepressant medicines including VIIBRYD may cause a certain type of eye problem called angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Call your healthcare provider if you have changes in your vision or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>. </p>
<p><span class="Bold">8. Low salt (sodium) levels in the blood.</span></p>
<p>Elderly people may be at greater risk for this. Symptoms may include: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or feeling unsteady </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, problems concentrating or thinking or memory problems </dd>
</dl>
<p><span class="Bold">What is VIIBRYD?</span></p>
<p>VIIBRYD is a prescription medicine used to treat a certain type of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> called Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD). It is important to talk with your healthcare provider about the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risk of not treating it.  You should discuss all treatment choices with your healthcare provider. </p>
<p>Talk to your healthcare provider if you do not think that your condition is getting better with VIIBRYD treatment. </p>
<p>It is not known if VIIBRYD is safe and effective in children. </p>
<p><span class="Bold">Who should not take VIIBRYD?</span></p>
<p><span class="Bold">Do not take VIIBRYD if you:</span></p>
<dl>
<dt>•</dt>
<dd>Take a Monoamine Oxidase Inhibitor (MAOI).  Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid. </dd>
<dt>•</dt>
<dd>Do not take an MAOI within 2 weeks of stopping VIIBRYD unless directed to do so by your healthcare provider. </dd>
<dt>•</dt>
<dd>Do not start VIIBRYD if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your healthcare provider. </dd>
</dl>
<p><span class="Bold">People who take VIIBRYD close in time to taking an MAOI may have serious or even life-threatening side effects.  Get medical help right away if you have any of these symptoms:</span></p>
<dl>
<dt>•</dt>
<dd>high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </dd>
<dt>•</dt>
<dd>uncontrolled <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span> </dd>
<dt>•</dt>
<dd>stiff muscles </dd>
<dt>•</dt>
<dd>rapid changes in heart rate or blood pressure </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (pass out) </dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking VIIBRYD?</span></p>
<p><span class="Bold">Before starting VIIBRYD, tell your healthcare provider if you:</span></p>
<dl>
<dt>•</dt>
<dd>have liver problems </dd>
<dt>•</dt>
<dd>have kidney problems </dd>
<dt>•</dt>
<dd>have or had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> </dd>
<dt>•</dt>
<dd>have bipolar disorder (<span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">manic depression</span>) or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> </dd>
<dt>•</dt>
<dd>have low sodium levels in your blood </dd>
<dt>•</dt>
<dd>have or had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems </dd>
<dt>•</dt>
<dd>drink alcohol </dd>
<dt>•</dt>
<dd>have any other medical conditions </dd>
<dt>•</dt>
<dd>Are pregnant or plan to become pregnant.  It is not known if VIIBRYD will harm your unborn baby.  Talk to your healthcare provider about the benefits and risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> during pregnancy. </dd>
<dt>•</dt>
<dd>Are breastfeeding or plan to breastfeed. It is not known if VIIBRYD passes into breast milk. You and your healthcare provider should decide if you should take VIIBRYD while breastfeeding. </dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines that you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. VIIBRYD and some medicines may interact with each other, may not work as well, or may cause serious side effects when taken together. </p>
<p><span class="Bold">Especially tell your healthcare provider if you take:</span></p>
<dl>
<dt>•</dt>
<dd>triptans used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> </dd>
<dt>•</dt>
<dd>medicines used to treat mood, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or thought disorders, including tricyclics, lithium, SSRIs, SNRIs, buspirone, or antipsychotics </dd>
<dt>•</dt>
<dd>tramadol </dd>
<dt>•</dt>
<dd>over-the-counter supplements such as tryptophan or St. John's Wort </dd>
<dt>•</dt>
<dd>nonsteroidal anti-inflammatory drugs (NSAIDS) </dd>
<dt>•</dt>
<dd>aspirin </dd>
<dt>•</dt>
<dd>warfarin (Coumadin, Jantoven) </dd>
<dt>•</dt>
<dd>mephenytoin (Mesantoin) </dd>
<dt>•</dt>
<dd>diuretics </dd>
</dl>
<p>Your healthcare provider or pharmacist can tell you if it is safe to take VIIBRYD with your other medicines. Do not start or stop any medicine while taking VIIBRYD without talking to your healthcare provider first. </p>
<p><span class="Bold">How should I take VIIBRYD?</span></p>
<dl>
<dt>•</dt>
<dd>Take VIIBRYD exactly as prescribed. Your healthcare provider may need to change the dose of VIIBRYD until it is the right dose for you. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Take VIIBRYD with food.</span> VIIBRYD may not work as well if you take it on an empty stomach. </dd>
<dt>•</dt>
<dd>If you miss a dose of VIIBRYD, take the missed dose as soon as you remember. If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses of VIIBRYD at the same time. </dd>
<dt>•</dt>
<dd>If you take too much VIIBRYD, call your healthcare provider or poison control center at 1-800-222-1222 right away, or get emergency treatment. </dd>
</dl>
<p><span class="Bold">What should I avoid while taking VIIBRYD?</span></p>
<dl>
<dt>•</dt>
<dd>VIIBRYD can cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how VIIBRYD affects you. </dd>
<dt>•</dt>
<dd>You should avoid drinking alcohol while taking VIIBRYD. See “What should I tell my healthcare provider before taking VIIBRYD?? </dd>
</dl>
<p><span class="Bold">What are the possible side effects of VIIBRYD?</span></p>
<p><span class="Bold">VIIBRYD may cause serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">See “What is the most important information I should know about VIIBRYD??</span></dd>
</dl>
<p>Common side effects in people who take VIIBRYD include: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>•</dt>
<dd>trouble sleeping </dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.  These are not all the possible side effects of VIIBRYD.  For more information, ask your healthcare provider or pharmacist. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">How should I store VIIBRYD?</span></p>
<p>Store VIIBRYD at room temperature (68°F to 77°F or 20°C to 25°C). </p>
<p><span class="Bold">Keep VIIBRYD and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of VIIBRYD.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VIIBRYD for a condition for which it was not prescribed.  Do not give VIIBRYD to other people, even if they have the same condition. It may harm them. </p>
<p>This Medication Guide summarizes the most important information about VIIBRYD. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about VIIBRYD that is written for healthcare professionals. </p>
<p>For more information about VIIBRYD call 1-800-678-1605. </p>
<p><span class="Bold">What are the ingredients in VIIBRYD?</span></p>
<p>Active ingredient: vilazodone hydrochloride </p>
<p>Inactive ingredients: lactose monohydrate, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and FD&amp;C Blue #1 (40 mg only), FD&amp;C Yellow #6 (20 mg only) and FD&amp;C Red #40 (10 mg only). </p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration. </p>
<p>Repackaged By:</p>
<p>Cardinal Health</p>
<p>Zanesville, OH 43701</p>
<p>L79010614</p>
<p>L79020714</p>
<p>Revised: March 2015 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_df42136f-202b-484a-90a6-e46b01c5b341"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel </h1>
<p class="First">Viibryd®</p>
<p>(vilazodone HCl) tablets</p>
<p>40 mg</p>
<p>Contains Approximately 1920 Tablets</p>
<div class="Figure">
<a name="id1111551193"></a><img alt="bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_fb7eb93b-3a28-489a-ab31-cb95fd344a76"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel </h1>
<p class="First">Viibryd®</p>
<p>(vilazodone HCl) tablets</p>
<p>40 mg</p>
<p>Contains Approximately 960 Tablets</p>
<div class="Figure">
<a name="id1758863977"></a><img alt="bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIIBRYD 		
					</strong><br><span class="contentTableReg">vilazodone hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-4624(NDC:0456-1140)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VILAZODONE HYDROCHLORIDE</strong> (VILAZODONE) </td>
<td class="formItem">VILAZODONE HYDROCHLORIDE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">40</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-4624-8</td>
<td class="formItem">1920  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55154-4624-2</td>
<td class="formItem">960  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022567</td>
<td class="formItem">04/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-4624)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1202dfc2-744a-43f7-aa43-d4b3bc7bbca2</div>
<div>Set id: bfef9e19-d0f5-40fa-954c-b73c812eb242</div>
<div>Version: 2</div>
<div>Effective Time: 20150911</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
